<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>842</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>11812154</PubmedId>
            <Abstract>The yellow fever 17D virus (YF17D) has several characteristics that are desirable for the development of new, live attenuated vaccines. We approached its development as a vector for heterologous antigens by studying the expression of a humoral epitope at the surface of the E protein based on the results of modelling its three-dimensional structure. This model indicated that the most promising insertion site is between beta-strands f and g, a site that is exposed at the external surface of the virus. The large deletion of six residues from the fg loop of the E protein from yellow fever virus, compared to tick-born encephalitis virus, leaves space at the dimer interface for a large insertion without creating steric hindrance. We have tested this hypothesis by inserting a model humoral epitope from the circumsporozoite protein of Plasmodium falciparum consisting of triple NANP repeats. Recombinant virus (17D/8) expressing this insertion flanked by two glycine residues at each end, is specifically neutralized by a monoclonal antibody to the model epitope. Furthermore, mouse antibodies raised to the recombinant virus recognize the parasite protein in an ELISA assay. Serial passage analysis confirmed the genetic stability of the insertion made in the viral genome and the resulting 17D/8 virus is significantly more attenuated in mouse neurovirulence tests than the 17DD vaccine. The fg loop belongs to the dimerization domain of the E protein and lies at the interface between monomers. This domain undergoes a low pH transition, which is related to the fusion of the viral envelope to the endosome membrane. It is conceivable that a slower rate of fusion, resulting from the insertion close to the dimer interface, may delay the onset of virus production and thereby lead to a milder infection of the host. This would account for the more attenuated phenotype of the recombinant virus in the mouse model and lower extent of replication in cultured cells. The vectorial capacity of the yellow fever virus is being further explored for the expression and presentation of other epitopes, including those mediating T-cell responses.</Abstract>
            <ArticleYear>2002</ArticleYear>
            <ArticlePages>873-85</ArticlePages>
            <ArticleTitle>Surface expression of an immunodominant malaria protein B cell epitope by yellow fever virus.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Bonaldo</LastName>
                    <ForeName>Myrna C</ForeName>
                </Author>
                <Author>
                    <LastName>Garratt</LastName>
                    <ForeName>Richard C</ForeName>
                </Author>
                <Author>
                    <LastName>Caufour</LastName>
                    <ForeName>Philippe S</ForeName>
                </Author>
                <Author>
                    <LastName>Freire</LastName>
                    <ForeName>Marcos S</ForeName>
                </Author>
                <Author>
                    <LastName>Rodrigues</LastName>
                    <ForeName>Mauricio M</ForeName>
                </Author>
                <Author>
                    <LastName>Nussenzweig</LastName>
                    <ForeName>Ruth S</ForeName>
                </Author>
                <Author>
                    <LastName>Galler</LastName>
                    <ForeName>Ricardo</ForeName>
                </Author>
            </Authors>
            <Affiliations>Departamento de Bioquímica e Biologia Molecular, Fundação Oswaldo Cruz Instituto Oswaldo Cruz, Rio de Janeiro, RJ 21045-900, Brazil.</Affiliations>
            <ArticleChemicalList>Antibodies, Monoclonal;Antigens, Protozoan;Epitopes, B-Lymphocyte;Immunodominant Epitopes;Malaria Vaccines;Vaccines, Attenuated;Vaccines, Synthetic;Viral Envelope Proteins;yellow fever virus envelope protein E</ArticleChemicalList>
            <ArticleMeshHeadingsList>Amino Acid Sequence; Animals; Antibodies, Monoclonal(immunology); Antigens, Protozoan(chemistry; genetics; immunology); Cell Line; Epitopes, B-Lymphocyte(chemistry; genetics; immunology); Gene Expression; Genome, Viral; Hydrogen-Ion Concentration; Immunodominant Epitopes(chemistry; genetics; immunology); Malaria(immunology; parasitology); Malaria Vaccines(administration &amp; dosage; adverse effects; genetics; immunology); Mice; Models, Molecular; Molecular Sequence Data; Neutralization Tests; Plasmodium falciparum(chemistry; genetics; immunology); Protein Structure, Tertiary; Sequence Alignment; Serial Passage; Survival Rate; Vaccines, Attenuated(adverse effects; genetics; immunology); Vaccines, Synthetic(administration &amp; dosage; adverse effects; genetics; immunology); Viral Envelope Proteins(chemistry; genetics; immunology); Yellow fever virus(genetics; isolation &amp; purification; pathogenicity; physiology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>315</Volume>
                <Issue>4</Issue>
                <Title>Journal of molecular biology</Title>
                <Issn>1089-8638</Issn>
                <MedlineTa>J Mol Biol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>(NANP)3</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>NANPNANPNANP</LinearSequence>
                        <StartingPosition>129</StartingPosition>
                        <EndingPosition>140</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P19597.2</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>5833</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 876</LocationOfData>
                <EpitopeId>43242</EpitopeId>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>Dominant epitope of CS protein of P. falciparum sporozoites. The circumsporozoite protein is the immunodominant surface antigen on the sporozoite (the infective stage of the malaria parasite that is transmitted from the mosquito to the vertebrate host). It harbors several tandem repeats of the epitopic sequence.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>9093</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>5833</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>P.falciparum [Mosquito Stage] [sporozoite]</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>38</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Vero cells infected with yellow fever virus expressing P. falciparum epitope are recognized by monoclonal antibody against the epitope. This antibody is also shown to immunoprecipitate E viral protein-epitope chimera from cell lysates.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>mAb 2A10</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>(NANP)3</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NANPNANPNANP</LinearSequence>
                                        <StartingPosition>129</StartingPosition>
                                        <EndingPosition>140</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P19597.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>5833</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <RecombinantOrganism>
                                    <SubType>Recombinant Organism</SubType>
                                    <RecombinantOrganismId>11090</RecombinantOrganismId>
                                </RecombinantOrganism>
                            </AntigenContainingObject>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 3</LocationOfData>
                        <BCellId>9095</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                                <Sex>F</Sex>
                                <Age>8 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>NANPNANPNANP</LinearSequence>
                                            <StartingPosition>129</StartingPosition>
                                            <EndingPosition>140</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P19597.2</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>5833</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>(NANP)3</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>11090</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>3 immunizations with 10&lt;sup&gt;5&lt;/sup&gt; PFU at weeks 0, 3 and 5. Mice were bled 2 wk after final dose.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Also intraperitoneal and intramuscular innoculations performed for comparative purposes. Subcutaneous administration was the most effective routs at eliciting anti-source protien antibodies.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Recognition of source protein in ELISA by sera from mice immunized subcutaneously with epitope-expressing yellow fever virus (YFV) is more reactive than sera from intraperitoneal or intramuscular inoculation.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>(NANP)3</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NANPNANPNANP</LinearSequence>
                                        <StartingPosition>129</StartingPosition>
                                        <EndingPosition>140</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P19597.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>5833</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <RecombinantOrganism>
                                    <SubType>Recombinant Organism</SubType>
                                    <RecombinantOrganismId>11090</RecombinantOrganismId>
                                </RecombinantOrganism>
                            </AntigenContainingObject>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>9094</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>5833</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>P.falciparum [Mosquito Stage] [sporozoite]</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Infection of Vero cells with yellow fever virus (YFV) expressing P. falciparum epitope is strongly neutralized by mAb against the epitope, while no neutralization of infection with WT YFV is obtained. This implies expression of the epitope on the virus surface.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>mAb 2A10</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>(NANP)3</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NANPNANPNANP</LinearSequence>
                                        <StartingPosition>129</StartingPosition>
                                        <EndingPosition>140</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P19597.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>5833</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <RecombinantOrganism>
                                    <SubType>Recombinant Organism</SubType>
                                    <RecombinantOrganismId>11090</RecombinantOrganismId>
                                </RecombinantOrganism>
                            </AntigenContainingObject>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

